chemotherapy for breast cancer stage 2
Tài liệu Screening for Breast Cancer: Systematic Evidence Review Update for the U. S. Preventive Services Task Force doc
Ngày tải lên :
14/02/2014, 21:20
... for Bre
Mortality
ast Cancer
(95% CrI)
NNI to Prevent 1 Breast
Cancer Death (95% CrI)
20 02 Review (age 65-74
y); Humphrey, et al,
20 02
2,3
Malmo and Swedish 2- C
trials
ounty 2 0.78 (0. 62- 0.99) ...
Overdiagnosis 20
Key Question 2b. What are the harms associated with CBE? 22
Key Question 2c. What are the harms associated with BSE? 22
Chapter 4. Discussion 23
Summary 23
Limitations 24
Future ... fair quality (Table 2) .
2
For women age 40-49 years,
results of the 20 02 meta-analysis indicated a relative risk for breast cancer mortality of 0.85
(95% CrI, 0.73-0.99) for women randomly...
- 95
- 1K
- 0
Tài liệu SCREENING FOR BREAST CANCER WITH MAMMOGRAPHY ppt
Ngày tải lên :
15/02/2014, 05:20
... treatment for breast cancer in Norway: comparative
analysis of cancer registry data. BMJ 20 11;343:d46 92.
20 . NHS cancer screening programmes. BASO Breast Audit 1999 /20 00.
www.cancerscreening.nhs.uk/breastscreen/publications.html ... background for our information in this
leaflet below.
SCREENING FOR BREAST CANCER
WITH MAMMOGRAPHY
What are the benefits and harms of attending a
screening programme for breast cancer? ... accounts for most of the observed breast cancer
specifi c mortality reductions in Australian women since the national screening
program began in 1991. Breast Cancer Res Treat. Epub 20 11 Sep 29 ....
- 15
- 528
- 3
Báo cáo sinh học: " Encapsulation of docetaxel in oily core polyester nanocapsule intended for breast cancer therapy" pptx
Ngày tải lên :
18/06/2014, 22:20
... NCs. The NCs' mean diameters were 127 .5 ± 19 .2 nm for NC-PLA206, 123 .8 ± 0.9
nm for NC-PLA207, 110.8 ± 8.6 nm for NC-PLA208, and 124 .6 ± 3.1 nm for NC-PCL.
These findings indicated a statistically ... poly(lactic acid)/polystyrene blends.
J Polym Sci B Polym Phys 20 02, 40 :22 48 -22 58.
[47] Kirchner B: Ionic Liquids. Volume 29 0. Berlin: Springer; 20 10.
[48]. Li PY, Lai PS, Hung WC, Syu WJ: Poly(l-lactide)-vitamin ... 3; S.D.: standard deviation between the three assays: PLA206 (105 kDa),
PLA207 (20 9 kDa), PLA208 (25 0 kDa), and PCL ( 72 kDa).
Figure 2. Influence of PVA concentrations (A,B) and molecular weights...
- 24
- 474
- 0
Báo cáo hóa học: " A Novel Docetaxel-Loaded Poly (e-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment" pot
Ngày tải lên :
22/06/2014, 00:20
... 3)
Polymer
PCNP 29 3 .2 ± 3.6 0.1 72 9.76 65.08 -48.70 ± 3.11 PCL
PFNP 20 1.7 ± 10.1 0.096 10. 02 69.10 - 12. 50 ± 0.86 PCL/F68
CCNP 28 1 .2 ± 5.5 0.145 -35.70 ± 2. 99 PCL
CFNP 22 2.7 ± 5.4 0.133 -20 .50 ± 1.34 PCL/F68
Note: ... in
human breast cancer cells and therefore have considerable
potential for treatment of breast cancer.
Keywords Nanoparticles Á MDR Á Pluronic F68 Á
Poly (e-caprolactone) Á Docetaxel Á Breast cancer
Introduction
Cancer ... drugs. Biomaterials 26 , 27 13 27 22 (20 05)
27 . M.P. Desai, V. Labhasetwar, E. Walter, R.J. Levy, G.L. Amidon,
The mechanism of uptake of biodegradable microparticles in
Caco -2 cells is size dependent....
- 10
- 363
- 0
Báo cáo sinh học: "Reasons for breast cancer heterogeneity" pptx
Ngày tải lên :
06/08/2014, 18:21
... more precise molecular classification of breast tumors.
BioMed Central
Journal of Biology
20 08,
77::
6
Published: 22 February 20 08
Journal of Biology
20 08,
77::
6 (doi:10.1186/jbiol67)
The ... understood breast cancer heterogeneity
better. Two recent papers in Genome Biology from the
laboratories of Carlos Caldas [1] and Eric Miska [2] use
molecular methods to classify breast cancers ... tumorigenicity in
breast cancer cells [14] and also invasion and metastasis
[15,16]. They are thought to be important in oncogenesis
(see [17,18] for reviews).
6 .2
Journal of Biology
20 08, Volume...
- 4
- 422
- 0
báo cáo khoa học: "Axillary lymph node dissection for breast cancer utilizing Harmonic Focus®" pps
Ngày tải lên :
09/08/2014, 02:20
... seromas following breast
cancer surgeries. Breast J 20 07, 13:588- 92.
21 . Burak WE Jr, Goodman PS, Young DC, Farrar WB: Seroma formation
following axillary dissection for breast cancer: risk factors ... Winer EP, Wolff AC, NCCN Breast Cancer Clinical Practice
Guidelines Panel: Breast cancer. Clinical practice guidelines in oncology. J
Natl Compr Canc Netw 20 09, 7 (2) : 122 - 92.
4. Giuliano AE, Hunt ... CS, Nelson BK: Seroma formation
following breast cancer surgery. Breast J 20 03, 5:385-8.
10. Woodworth PA, McBoyle MF, Helmer SD, Beamer RL: Seroma formation
after breast cancer surgery: incidence...
- 5
- 349
- 0
báo cáo khoa học: "Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer" doc
Ngày tải lên :
09/08/2014, 02:21
... localized
estrogen receptors in human breast cancer. Cancer Res 1990,
50 12: 3545-3550.
9. British Breast Group: Assessment of response to treatment in advanced
breast cancer. Lancet 1974, 2: 38-39.
10. Hayward ... estradiol hypersensitivity in human breast cancer cells. J Clin
Endocrinol Metab 1995, 8010 :29 18 -29 25.
15. SOLE trial Newsletter No 8, March 20 11. [http://www.
breastinternationalgroup.org/LinkClick.aspx?fileticket=dmcZc0avwBc%
3d&tabid =23 41].
doi:10.1186/1477-7819-9-101
Cite ... Surgical Oncology 20 11, 9:101
http://www.wjso.com/content/9/1/101
Page 2 of 4
RESEARC H Open Access
Clinical relevance of “withdrawal therapy” as a
form of hormonal manipulation for breast cancer
Amit...
- 4
- 253
- 0
báo cáo khoa học: "Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer" pdf
Ngày tải lên :
09/08/2014, 02:21
... 0.000
Hemoglobin
121 . 72 21 . 92 123 .93 28 .26 0.417
Serum albumin
42. 83±4 .25 42. 18±4. 62 0 .21 1
CEA
15.986±67.377 4.357±9.1 92 0.081
CA199
175.836±803.631 81 .27 0±394.9 42 0 .25 5
Comorbid illness ... and
22
Table 2 Patient preoperative status
NACT (%)
n =110
SURG (%)
n =26 7
P value
Body mass index (BMI)
22 . 92 3. 12 23.03±3.56 0.773
White blood cells
5 .29 ±1.84 6 .25 2. 10 0.000 ...
21
-T2
-T3
-T4
90(81.8%)/ 73(66.4%)
20 (18 .2% )/ 12( 10.9%)
25 1(94%) /22 1( 82. 8%)
16(6.0%)/17(6.4%)
Pathological N Staging
-N0
-N1
-N2
-N3
34(30.9%)
47( 42. 7%)
17(15.5%)
12( 10.9%)...
- 27
- 239
- 0
Báo cáo khoa học: "Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer" pot
Ngày tải lên :
09/08/2014, 03:22
... Pharmacol
1983, 32: 2045 -20 52.
20 . Wolf DM, Jordan VC: Gynecologic complications associated with long-
term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 19 92,
45 (2) :118 -28 .
21 . Wiebe VJ, ... Agency for Research
on Cancer, Lyon, France 1996, 66 :25 3-365.
11. Swerdlow AJ, Jones ME: Tamoxifen treatment for breast cancer and risk
of endometrial cancer: a case-control study. J Natl Cancer ... tamoxifen for prevention of
breast cancer. Br J Cancer 1989, 60(1): 126 -31.
4. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM:
Endometrial cancer in tamoxifen-treated breast cancer...
- 3
- 427
- 0
Báo cáo khoa học: "Predictive factors for breast cancer in patients diagnosed atypical ductal hyperplasia at core needle biopsy" doc
Ngày tải lên :
09/08/2014, 04:21
... Yes 8 (25 .8%) 4 (50%) 33.3% 0.186
No 23 (74 .2% ) 4 (50%) 14.8%
Mass + MIC on MMG Yes 1 (3.1%) 2 (22 .2% ) 66.7% 0. 52
No 31 (96.9%) 7 (77.8%) 18.4%
Lesion size 1 cm 23 (69.7%) 3 (30%) 11.5% 0. 024
> ... 1.147 -25 .105 0.033
Mass USG 2. 667 0 .29 2 -24 .345 0.385
MIC USG 4.571 0.758 -27 .577 0.097
Mass + MIC USG 14.571 1.315-161.418 0. 029
Needle size 1.50 0.155-14.557 0. 727
Number of cores 1.50 0 .24 4-9 .21 9 ... Underestimation
rate (22 .2% )
P value
(Chi-square)
Benign (n = 35) Malignancy (n = 10)
Age (years) < 50 28 (80%) 3 (30%) 9.7% 0.003
50 7 (20 %) 7 (70%) 50%
Mass on MMG Yes 10 ( 32. 3%) 4 (50%) 28 .6% 0.351
No 21 ...
- 5
- 319
- 0
